MannKind and One Drop Sign Collaboration Agreement to Integr

[kite]

www.globenewswire.com/news-release/2019/08/05/1896889/0/en/MannKind-and-One-Drop-Sign-Collaboration-Agreement-to-Integrate-Bluetooth-Connected-Inhaler-with-Dose-Detection-into-the-One-Drop-Platform.html


WESTLAKE VILLAGE, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) and One Drop today announced that they have signed a collaborative agreement that is intended to integrate MannKind’s BluHale® accessory device into the One Drop platform. BluHale is a Bluetooth-connected accessory that attaches to the Afrezza® inhaler and is designed to convey real-time information about inhalation effort and insulin dose. The goal of this collaboration is to provide a seamless experience for Afrezza patients, including automatic tracking of their insulin doses as well as other important health information on the One Drop platform. The agreement is expected to bring One Drop’s award winning user experience to Afrezza users, empowering them with AI-enabled glucose forecasts, predictive insights, and the opportunity to connect one-on-one with One Drop’s certified diabetes educators, an educational service that has been recognized by the American Diabetes Association.



“Earlier this year, One Drop announced clinical data that demonstrated using Afrezza with One Drop provided a significant improvement in A1C levels. We now look forward to integrating automatic dose detection into their platform in order to further evolve the patient experience,” said Michael Castagna, CEO of MannKind Corporation. “We believe the future of diabetes management will increasingly depend on data collected on a smartphone that provides real time decision support insights that will help patients and providers achieve improved outcomes.”



“For too long, people with diabetes have been trying to make decisions about what to do and when to do it by looking in the rear-view mirror,” said Jeff Dachis, CEO of One Drop. “Having automated dose detection with Afrezza will be a huge step forward in helping to remove burden from people’s care regimen, and will enable powerful, data-driven insights, potentially leading to even better patient health outcomes.”

[sportsrancho]

[sportsrancho]

“For too long, people with diabetes have been trying to make decisions about what to do and when to do it by looking in the rear-view mirror,” said Jeff Dachis, CEO of One Drop. “Having automated dose detection with Afrezza will be a huge step forward in helping to remove burden from people’s care regimen, and will enable powerful, data-driven insights, potentially leading to even better patient health outcomes.”

[sportsrancho]

Sorry Kite, I swear when I posted I saw no new posts whatsoever but obviously the threads should be combined and everything should be moved over here.

[kite]

Aug 5, 2019 8:31:30 GMT -5 sportsrancho said:

Sorry Kite, I swear when I posted I saw no new posts whatsoever but obviously the threads should be combined and everything should be moved over here.

Ahh no worries! I'm glad you're keeping on top of things! (as usual, and much appreciated for it)

[Clement]

"to provide a seamless experience for Afrezza patients, including automatic tracking of their insulin doses"

Read more: mnkd.proboards.com/thread/11403/mannkind-drop-collaboration-agreement-integr#ixzz5vjXJvgD5

This new capability for BluHale can be extended (with just a little more software now that all the hardware is there) for T1's on a pump, to allow a seamless record of an Afrezza correction dose so that the pump loop can respond (or not) accordingly.  Very cool.

[prcgorman2]

I've read where specially trained dogs have been used to smell and detect when a child is going into hypoglycemia while they're sleeping so I've wondered if BluHale could be instrumented with exhale sensors to estimate blood glucose based on compounds found in exhaled air.

[Clement]

In future ....... and wouldn't it look nice on a Dexcom. A PWD could conceivably show their BG history to their doc with automatic notations of Afrezza dosage.

[peppy]

"BluHale is a Bluetooth-connected accessory that attaches to the Afrezza® inhaler and is designed to convey real-time information about inhalation effort and insulin dose. "
this is going to come in handy.
this is the trial.
UTHR.

[paul]

Aug 5, 2019 9:24:31 GMT -5 peppy said:

"BluHale is a Bluetooth-connected accessory that attaches to the Afrezza® inhaler and is designed to convey real-time information about inhalation effort and insulin dose. "
this is going to come in handy.
this is the trial.
UTHR.

Does the device recognize what size cartridge is being used?

[longliner]

Apple Store to sell One Drop, it is their only diabetes product.

[peppy]

Aug 5, 2019 10:36:37 GMT -5 paul said:

Aug 5, 2019 9:24:31 GMT -5 peppy said:

"BluHale is a Bluetooth-connected accessory that attaches to the Afrezza® inhaler and is designed to convey real-time information about inhalation effort and insulin dose. "
this is going to come in handy.
this is the trial.
UTHR.

Does the device recognize what size cartridge is being used?

If the device can detect the insulin dose, I would think the device could detect the cartridge size.
4U 8U 12U and all.

[ktim]

Aug 5, 2019 11:32:57 GMT -5 peppy said:

Aug 5, 2019 10:36:37 GMT -5 paul said:

Does the device recognize what size cartridge is being used?

If the device can detect the insulin dose, I would think the device could detect the cartridge size.
4U 8U 12U and all.

The original device did not detect cartridge size.  If there is a way of doing that without redesigning the dreamboat inhaler then it seems they would have done it before starting to promote BluHale for non-clinical use.  It would seem almost pointless without the ability to detect the size.

[prcgorman2]

Found the following old information that makes me think estimating cartridge size might be possible using sound profiles.

From: www.mannkindcorp.com/Collateral/Documents/English-US/Innovation%20In%20Drug%20Delivery%20by%20Inhalation.pdf

"Recognizing the criticality of these parameters, MannKind developed a compact and wireless pressure profiling technology, called BluHale®, to rapidly advance and understand the patient/delivery system interaction.

A small, discreet electro-acoustic sensor was used to measure the sound emitted by air flow through the system. Since higher flows (and greater sounds) result from higher pressures, the sensor output was calibrated to applied pressure.

Sound is a unique characteristic for inhalation devices because it generally emanates from the system in all directions. This allows it to be measured remotely unlike traditional pressure/flow sensors that must be located within the flow path. Data can be easily collected during dose administration without affecting sensor integrity or changing airflow dynamics through the device. Additionally, the inhaler interface with the subject is unchanged because of the compact nature of the electro-acoustic sensing technology and its simple adaption onto the device. The sensor, along with circuitry, is housed within a jacket-like frame that is easily affixed onto a dry-powder inhaler (see Figure 8)."

[ktim]

prcgorman2... it seems at least physically plausible that might be the case, that there would be some minor acoustic difference depending on how much powder is in the flow stream at a given time. If patients using dreamboat can hear a difference between different sized cartridge then certainly a sensor could do it, and a sensor might be able to make the distinction even if a person cannot. In my opinion BluHale would be a nothing burger without it, so I'll give the benefit of the doubt that MNKD has added the capability before starting to market to patients for logging purposes.